Alefacept is a genetically engineered immunosuppressive drug. It was sold under
the brand name Amevive in Canada, the United States, Israel, Switzerland and ...
Nov 16, 2011 ... Astellas Pharma U.S. Inc. (Astellas) has voluntarily discontinued the promotion,
manufacturing, distribution and sales of Amevive (alefacept), ...
Alefacept is the first biological agent approved by the US Food and Drug
Administration (FDA) for the treatment of moderate to severe chronic plaque
Alefacept is a recombinant fusion protein of lymphocyte function associated
antigen-3 (LFA-3) and immunoglobulin G dimer that acts to inactive T cells, and is
Amevive (alefacept) is a protein that reduces specific actions of the immune
system that are involved in causing psoriasis. Amevive is used to treat plaque ...
intravenous injection contains 7.5 mg alefacept per 0.5 mL of reconstituted
solution. ... administration, the mean volume of distribution of alefacept was 94
Amevive (alefacept): For moderate to severe chronic plaque psoriasis.. New
approved drug details including side effects, uses and general information.
Feb 28, 2016 ... Alefacept. Alefacept belongs to the class of biological response modifiers called
T-cell blockers. It is currently approved in the US for the ...
Jan 11, 2012 ... ASHP represents pharmacists who serve as patient care providers in acute and
ambulatory settings. The organization's more than 43000 ...
Alefacept provides sustained clinical and immunological effects in new-onset
type 1 diabetes patients. Mark R. Rigby,<sup>1</sup> Kristina M. Harris,<sup>2</sup> Ashley Pinckney,<sup>3</sup> ...